Mezzion Pharma Co.,Ltd.
Financials
Valuation Metrics
Mezzion Pharma Co.,Ltd.'s Market Cap is ₩2.1T. At end of 2025 it was ₩2.8T. Ranked #215 of 2,419 in KR market (top 9%), #47 of 1,638 on KOSDAQ (top 3%), #20 of 231 in Pharmaceuticals, Biotechnology & Life Sciences (top 9%) by Market Cap.
Investment Metrics(as of 2026-10-07)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 2.09T KRW | KR#215/2,419 Sec#20/231 |
| Revenue | 8.43B KRW | KR#2,300/2,419 Sec#179/231 |
| Net Income | -27.39B KRW | KR—/2,419 Sec—/231 |
| Total Assets | 125.25B KRW | KR#1,619/2,419 Sec#128/231 |
| Net Assets | 39.04B KRW | KR#2,064/2,419 Sec#183/231 |
| Employees | 18 | KR#2,259/2,419 Sec#213/231 |
| Value | ||
| P/B | 53.47x | KR#2,411/2,419 Sec#230/231 |
| P/S | 247.71x | KR#2,401/2,419 Sec#218/231 |
| FCF Yield | -0.80% | KR—/2,419 Sec—/231 |
| Profitability | ||
| ROE | -70.16% | KR#2,321/2,419 Sec#209/231 |
| ROA | -21.87% | KR#2,259/2,419 Sec#180/231 |
| Op. Margin | -223.13% | KR#2,335/2,419 Sec#186/231 |
| Revenue Growth | 6.92% | KR#1,076/2,419 Sec#104/231 |
| Financial Health | ||
| Debt Ratio | 220.79% | KR#2,151/2,419 Sec#221/231 |
| Total Debt | 15.58B KRW | KR#1,484/2,419 Sec#125/231 |
| FCF | -16.73B KRW | KR#1,852/2,419 Sec#175/231 |
| Cash | 40.31B KRW | KR#845/2,419 Sec#52/231 |
| Current Ratio | 0.68x | KR#2,042/2,419 Sec#195/231 |
| Performance | ||
| 1Y Return | 7.78% | KR#840/2,419 Sec#53/231 |
| 1M Return | 2.57% | KR#943/2,419 Sec#91/231 |
| From 52W High | -62.26% | KR#1,986/2,419 Sec#168/231 |
| 1Y MDD | -70.47% | KR#2,010/2,419 Sec#175/231 |
| Trading | ||
| Volume | 69,766 shares | KR#976/2,419 Sec#112/231 |
| Trading Value | 4.86B KRW | KR#392/2,419 Sec#47/231 |
| Foreign Own. | 24.44% | KR#171/2,419 Sec#7/231 |
| Per Share | ||
| EPS | -891 KRW | KR—/2,419 Sec—/231 |
| BPS | 1,270 KRW | KR#2,249/2,419 Sec#202/231 |
Company Info
Mezzion, established in 2002, is a KOSDAQ-listed pharmaceutical manufacturing and sales corporation. The company develops various new drugs, including treatments for erectile dysfunction and benign prostatic hyperplasia, and has licensed out and exported products to major countries such as the United States. Recently, Mezzion has focused on developing a single ventricle disease treatment, having received FDA approval for an additional clinical protocol in 2023 and currently proceeding with further clinical trials. The company is headquartered in Gangnam-gu, Seoul.